

NEBRASKA MEDICAID AD HOC FEE SCHEDULE

**This fee schedule is subject to change, as further Center of Medicare & Medicaid's (CMS) guidance occurs.
The updates in this version are reflected in red.**

COVID-19 CODES

CODE	MOD	DESCRIPTION	PA	COMMENTS	COPAY	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS THROUGH TO 3/14/2021	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS ON OR AFTER 3/15/2021
0034A		JANSEN COVID-19 VACCINE ADMINISTRATION - BOOSTER		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 11/2/2021
0051A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - First dose					\$36.94 Effective 12/27/2021
0052A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - Second dose					\$36.94 Effective 12/27/2021
0053A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - Third dose					\$36.94 Effective 12/27/2021
0054A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - Booster					\$36.94 Effective 12/27/2021
0071A		Pfizer-BioNTech Covid-19 Pediatric Vaccine - Administration - First dose		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 11/2/2021
0072A		Pfizer-BioNTech Covid-19 Pediatric Vaccine - Administration - Second dose		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 11/2/2021
0073A		IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE)					\$36.94 Effective 1/4/2022
0004A		Pfizer-BioNTech Covid-19 Vaccine Administration - Booster		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 9/22/2021
0064A		Moderna Covid-19 Vaccine (Low Dose) Administration - Booster		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 10/20/2021
0003A		PFIZER BIONTECH COVID-19 ADM SARSCOV2 30MCG/0.3ML 3RD DOSE		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 8/12/2021
0013A		MODERNA COVID-19 ADM SARSCOV2 100MCG/0.5ML 3RD DOSE		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 8/12/2021
M0201		COVID-19 VACCINE ADMINISTRATION INSIDE A PATIENT'S HOME		RATE CHANGE \$33.05 Effective 1/1/2022			\$32.50 Effective 8/6/2021
M0220		INJECTION, TIXAGENIVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS; INJECTION AND ADMINISTRATION MONITORING.					\$135.31 Effective 12/8/2021
M0221		INJECTION, TIXAGENIVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS; INJECTION AND ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE					\$225.36 Effective 12/8/2021
M0222		INTRAVENOUS INJECTION, BEBTELOVIMAB. INCLUDES INJECTION AND POST ADMINISTRATION MONITORING					\$350.50 Effective 2/11/2022
M0223		INTRAVENOUS INJECTION, BEBTELOVIMAB. INCLUDES INJECTION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE; THIS INCLUDES A BENEFICIARY'S HOME THAT HAS BEEN MADE PROVIDER-BASED TO THE HOSPITAL DURING THE COVID-19 PUBLIC HEALTH EMERGENCY					\$550.50 Effective 2/11/2022
Q0221		INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40kg) WITH NO KNOWN SARS-COV-2 EXPOSURE, WHO EITHER HAVE MODERATE TO SEVERELY COMPROMISED IMMUNE SYSTEMS OR FOR WHOM VACCINATION WITH ANY AVAILABLE COVID-19 VACCINE IS NOT RECOMMENDED DUE TO A HISTORY OF SEVERE ADVERSE REACTION TO A COVID-19 VACCINE(S) AND/OR COVID-19 VACCINE COMPONENT(S) 600mg					Not covered while federally supplied Effective 2/24/2022
Q0222		INJECTION, BEBTELOVIAMAB, 175MG					Not covered while federally supplied Effective 2/11/2022
M0240		INTRAVENOUS INFUSION OR SUBCUTANEOUS INJECTION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION OR INJECTION, AND POST ADMINISTRATION MONITORING, SUBSEQUENT REPEAT DOSES.		RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 7/30/2021

						MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS THROUGH TO 3/14/2021	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS ON OR AFTER 3/15/2021
CODE	MOD	DESCRIPTION	PA	COMMENTS	COPAY		
M0241		INTRAVENOUS INFUSION OR SUBCUTANEOUS INJECTION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION OR INJECTION, AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE, SUBSEQUENT REPEAT DOSES.		RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 7/30/2021
M0244		INTRAVENOUS INFUSION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION AND POST ADMINISTRATION MONITORING		RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 5/6/2021
M0246		INTRAVENOUS INFUSION, BAMLANIVIMAB AND ETESEVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONI HOME OR RES...DURING COVID-19 PHE		RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 5/6/2021
M0247		INTRAVENOUS INFUSION, SOTROVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING		RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 5/26/2021
M0248		INTRAVENOUS INFUSION, SOTROVIMAB, INCLUDES INFUSION AND POST ADMIN MONI IN THE HOME OR RESIDENCE		RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 5/26/2021
M0249		INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS.. 1ST DOSE		RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 6/24/2021
M0250		INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS.. 2nd Dose		RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 6/24/2021
Q0247		INJECTION, SOTROVIMAB, 500mg					\$2,394.00 Effective 5/26/2021
Q0249		INJECTION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS.. WITH COVID-19...ECMO ONLY 1 MG					\$6.57 Effective 6/24/2021
D0606		MOLECULAR TESTING FOR A PUBLIC HEALTH RELATED PATHOGEN, INCLUDING CORONA VIRUS					\$51.31
D1701		PFIZER 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
D1702		PFIZER 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
D1703		MODERNA 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
D1704		MODERNA 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
D1707		JANSSEN SINGLE DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
0031A		JANSSEN SINGLE DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT		RATE CHANGE \$36.94 Effective 1/1/2022		\$28.39	\$37.25
87426	QW	INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE, (EG, ENZYME IMMUNOASSAY, ENZYME-LINKED IMMUNOSORBENT ASSAY,		COVID EMERGENCY PERIOD		\$35.33	
87428	QW	INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE, (EG, ENZYME IMMUNOASSAY ENZYME-LINKED, IMMUNOSORBENT ASSAY, FLUORESC		COVID EMERGENCY PERIOD		\$63.59	\$30.94 EFFECTIVE 1/1/2022
87635	QW	AMPLIFIED DNA OR RNA PROBE DETECTION OF SARS CORONORIVUS		COVID EMERGENCY PERIOD		\$51.31	
M0243		INTRAVENOUS INFUSION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION AND POST ADMINISTRATION MONITORING		RATE CHANGE \$404.92 Effective 12/08/2021		\$309.60	\$404.78 Effective 5/6/2021
M0245		INTRAVENOUS INFUSION, BAMLANIVIMAB AND ETESEVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING		RATE CHANGE \$404.92 Effective 12/08/2021		\$309.60	\$404.78 Effective 5/6/2021
C9803		HOSPITAL OUTPATIENT CLINIC VISIT SPECIMEN COLLECTION FOR (SARS-COV-2) (COVID-19), ANY SPECIMEN SOURCE		COVID EMERGENCY PERIOD		\$23.00	
G2023		SPECIMEN COLLECTION FOR COVID-19, ANY SPECIMEN SOURCE		COVID EMERGENCY PERIOD		\$23.46	
G2024		SPECIMEN COLLECTION FOR COVID-19, FROM AN INDIVIDUAL IN A SNF OR LABORATORY ON BEHALF OF A HOME HEALTH AGENCY, ANY SPECIMEN SOURCE		COVID EMERGENCY PERIOD		\$25.46	
U0001		CDC 2019 NOVEL CORONAVIRUS (2019-NCOV) REAL-TIME RT-PCR DIAGNOSTIC PANEL		COVID EMERGENCY PERIOD		\$35.92	
U0002		NON-CDC SARS-COV-2/2019-NCOV (COVID-19)		COVID EMERGENCY PERIOD		\$51.31	
U0002	QW	NON-CDC SARS -COV-2/2019 -NCOV		COVID EMERGENCY PERIOD		\$51.31	

						MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS THROUGH TO 3/14/2021	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS ON OR AFTER 3/15/2021
CODE	MOD	DESCRIPTION	PA	COMMENTS	COPAY		
U0003		INFECTIOUS AGENT DETECTION BY DNA OR RNA;COVID-19,AMPLIFIED PROBE TECHNIQUE,HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R		COVID EMERGENCY PERIOD		\$100.00	\$75.00
U0004		COVID-19,ANY TECHNIQUE,MULTIPLE TYPES OR SUBTYPES,NON-CDC, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R		COVID EMERGENCY PERIOD		\$100.00	\$75.00
U0005		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$25.00	
0001A		PFIZER 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022		\$16.94	\$37.25
0002A		PFIZER 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022		\$28.39	\$37.25
0011A		MODERNA 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022		\$16.94	\$37.25
0012A		MODERNA 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022		\$28.39	\$37.25
0202U		INFECTIOUS DISEASE(BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION), PATHOGEN-SPECIFIC NUCLEIC ACID (DNA OR RNA), 22 TARGETS INCLUDING SEVERE A		COVID EMERGENCY PERIOD		\$298.60	\$416.78 EFFECTIVE 1/1/2021
0223U		INFECTIOUS DISEASE(BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION), PATHOGEN-SPECIFIC NUCLEIC ACID (DNA OR RNA), 22 TARGETS INCLUDING SEVERE A		COVID EMERGENCY PERIOD		\$298.60	\$416.78 EFFECTIVE 1/1/2021
0224U		ANTIBODY, SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2(SARS-COV-2) (CORONAVIRUS DISEASE YCOVID-19"), INCLUDES TITER(S), WHEN PERFORMED (DO		COVID EMERGENCY PERIOD		\$42.13	
0225U		INFECTIOUS DISEASE (BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION) PATHOGEN-SPECIFIC DNA AND RNA, 21 TARGETS, INCLUDING SEVERE ACUTE RESPIRAT		COVID EMERGENCY PERIOD		\$298.60	\$416.78 EFFECTIVE 1/1/2021
0226U		SURROGATE VIRAL NEUTRALIZATION TEST (SVNT), SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCOVID-19"), ELI		COVID EMERGENCY PERIOD		\$42.28	
0240U		INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION),PATHOGEN-SPECIFIC RNA, 3 TARGETS (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 YSARS		COVID EMERGENCY PERIOD		\$142.63	
0241U		INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION),PATHOGEN-SPECIFIC RNA, 4 TARGETS (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 YSARS		COVID EMERGENCY PERIOD		\$142.63	
86328		IMMUNOASSAY FOR INFECTIOUS AGENT ANTIBODY(IES), QUALITATIVE OR SEMIQUANTITATIVE, SINGLE STEP METHOD (EG, REAGENT STRIP); (SARS-COV-2)(COVID-19)		COVID EMERGENCY PERIOD		\$45.23	\$45.28 EFFECTIVE 1/1/2022
86408		SCREENING TEST FOR DETECTION OF SEVERE ACUTE RESPIRATORY SUNDROME CORONAVIRUS 2		COVID EMERGENCY PERIOD		\$42.13	
86409		MEASUREMENT OF NEUTRALIZING ANTIBODY TO SEVERE ACUTE RESPIRATORY SYNDROME CORONA		COVID EMERGENCY PERIOD		\$79.61	
86769		ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2(SARS-COV-2) (COVID-19)		COVID EMERGENCY PERIOD		\$42.13	
87301		INFECTIOUS AGENT ANTIGEN DETECTION BY ENZYME IMMUNOASSAY TECHNIQUE, QUALITATIVE OR SEMIQUANTITATIVE, MULTIPLE STEP METHOD; ADENO VIRUS		COVID EMERGENCY PERIOD		\$11.98	
87426		INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE,(EG, ENZYME IMMUNOASSAY YELIA ", ENZYME-LINKED IMMUNOSORBENT ASSAY YELISA ", IMMUNOCH		COVID EMERGENCY PERIOD		\$35.33	
87428		INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE,(EG, ENZYME IMMUNOASSAY YELIA ", ENZYME-LINKED IMMUNOSORBENT ASSAY YELISA ", FLUORESC		COVID EMERGENCY PERIOD		\$63.59	\$30.94 EFFECTIVE 1/1/2022
87635		DETECTION OF SARS-COV-2 AND ANY PAN-CORONAVIRUS TYPES OR SUBTYPES;INFECTIOUS AGENT DETECTION BY NUCLEIC ACID(DNA OR RNA; SEVERE ACUTE RESPIRATOR		COVID EMERGENCY PERIOD		\$51.31	

						MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS THROUGH TO 3/14/2021	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS ON OR AFTER 3/15/2021
CODE	MOD	DESCRIPTION	PA	COMMENTS	COPAY		
87636		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$142.63	
87637		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$142.63	
87811		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$41.38	